Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

Data Presented at ASCO Breast Cancer Symposium; Additional Positive Results

Seen Since Presentation at ASCO Annual Meeting in June Phase I Trial Expanding to Include Alvespimycin Plus Trastuzumab Plus

Paclitaxel Regimen

HAYWARD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented updated data from a Phase 1 clinical trial showing that alvespimycin, its second-generation Hsp90 inhibitor, demonstrated antitumor activity and tolerability in combination with trastuzumab (Herceptin(R)) in patients with refractory HER2-positive metastatic breast cancer, and in patients with refractory ovarian cancer who were progressing on standard chemotherapy. Data from the ongoing trial in patients with solid tumors were presented on Friday, September 7, 2007 by Shanu Modi, M.D., Memorial Sloan Kettering Cancer Center, in a poster, titled, "Alvespimycin (KOS-1022) and Trastuzumab (T): Activity in HER2+ Metastatic Breast Cancer (MBC)" at the 2007 Breast Cancer Symposium of the American Society of Clinical Oncology (ASCO), San Francisco, CA.

"Alvespimycin continues to demonstrate meaningful antitumor activity in patients with highly refractory HER2-positive metastatic breast cancer and ovarian cancer, with additional positive Phase 1 data showing sustained responses and clinical benefit," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Our strategy is to pursue potentially a broad and fast-to-market development pathway for alvespimycin in HER2-positive metastatic breast cancer. We are expanding the Phase 1 trial to include an alvespimycin plus trastuzumab plus paclitaxel regimen to establish a saf
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 Touro College has announced that it ... for one of five media marijuana licenses to be issued ... of Health (DOH).  If CanniCare is selected, ... "Our college is supportive of medicinal development ... the Touro College System. "There is still a great deal ...
(Date:7/29/2015)... and PITTSBURGH , July 29, ... announced that it received regulatory clearance from the European ... its proposed acquisition of Perrigo Company plc (NYSE: ... Robert J. Coury commented, "Today marks yet ... acquisition of Perrigo and serves as further affirmation of ...
(Date:7/29/2015)... July 29, 2015 Legal-Bay LLC, The Lawsuit Settlement ... Goodwin in the Southern District of West ... trial that was initially set to start in November. The ... but new plaintiffs were added and now it involves 39 ... 7 th , according to an article in Reuters. The ...
Breaking Medicine Technology:Touro College Announces Support for CanniCare's Medical Cannabis License Application 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3
(Date:7/29/2015)... ... 29, 2015 , ... It is unique for a health center to dedicate ... care. One that is very hands on and resident oriented, and one to which ... bringing great passion and energy, as well as a strong commitment to helping seniors ...
(Date:7/29/2015)... Wis. (PRWEB) , ... July 29, 2015 , ... ... its first two patients in a Clinical Performance Study for the Invisiport at ... 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative to ...
(Date:7/29/2015)... ... July 29, 2015 , ... TransFlip is an all new dynamic transition pack ... for FCPX, these transitions are easy to apply and modify for any skill-level user. ... over 60 preset styles, kinetic flipping panel animations are just a few clicks away. ...
(Date:7/29/2015)... ... 29, 2015 , ... Zofran lawsuits around the nation are ... (JPML), according to court documents.* Attorneys handling Zofran lawsuits provide timely ... Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate and defendant in national Zofran ...
(Date:7/29/2015)... ... July 29, 2015 , ... The New Foundation ... which will by the end will cost the 501(c) organization nearly $1 million, will ... anti-ligature requirements. , “We took it down to the studs,” said Geraldine Leary, ...
Breaking Medicine News(10 mins):Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3
... American Healthcare,Corporation (Nasdaq: UAHC ), which owns ... care organization in,Tennessee, today announced financial results for ... Revenues increased five percent to $6.5 million for ... with revenues of $6.2 million for,the first quarter ...
... HILL, N.C., Nov. 4 As biopharmaceutical,companies ... development,opportunities, fixed-dose combination (FDC) products have become ... an effort to better,understand the development strategies ... study was conducted by Best Practices, LLC, ...
... program, HOUSTON, Nov. 4 Carriage Services, Inc.,(NYSE: CSV ) today announced results for the third quarter ... were as follows:, Third Quarter Selected Financial Results (amounts in millions, except per share amounts), ... Q3 ... ...
... brains mature earlier, study says , , TUESDAY, Nov. 4 (HealthDay ... have better control of their movements than boys with the ... published in the Nov. 4 issue of Neurology , ... children without the disorder did twice as well as boys ...
... produces noticeable results, study says , , TUESDAY, Nov. 4 ... or prescription painkillers are less likely to continue using ... combination of detoxification medications, rather than short-term drug therapy, ... have been shown to be effective in treating opioid ...
... decades, study shows , , TUESDAY, Nov. 4 (HealthDay News) -- ... improved significantly over the past three decades, but the first ... study shows. , The study looked at the experiences of ... heart attacks between 1979 and 2005. , "There were two ...
Cached Medicine News:Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 2Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 3Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 4Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 5Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 6Health News:New Study Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development 2Health News:Carriage Services Announces Third Quarter 2008 Results 2Health News:Carriage Services Announces Third Quarter 2008 Results 3Health News:Carriage Services Announces Third Quarter 2008 Results 4Health News:Carriage Services Announces Third Quarter 2008 Results 5Health News:Carriage Services Announces Third Quarter 2008 Results 6Health News:Carriage Services Announces Third Quarter 2008 Results 7Health News:Carriage Services Announces Third Quarter 2008 Results 8Health News:Carriage Services Announces Third Quarter 2008 Results 9Health News:Carriage Services Announces Third Quarter 2008 Results 10Health News:Carriage Services Announces Third Quarter 2008 Results 11Health News:Carriage Services Announces Third Quarter 2008 Results 12Health News:Extended Therapy Helps Drug-Addicted Teens 2Health News:Extended Therapy Helps Drug-Addicted Teens 3Health News:Sudden Death Risk Highest 30 Days After Heart Attack 2
Single side double clamp knife holder for the Vibratome 8000...
... The Starter Package is a solid ... The package includes the Vibratome Plus, ... v-block adapter, specimen mounts w/1/2" head, ... ease in all of your sectioning ...
... Package is the ultimate solution ... includes the Vibratome 3000 Deluxe ... package accessory kit, additional mounting ... 1/2" head, rotating stage, and ...
... is the best way to ... package includes the Vibratome 1500, ... blocks, v-block adapter, specimen mounts ... blade for the ultimate in ...
Medicine Products: